Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × UNKNOWN × aumolertinib × Clear all

Phase

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 7 OTHER 5 UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 5 Radiotherapy 3 Radiotherapy, Intensity-Modulated 2 Radiation 2 Epirubicin 2 Docetaxel 2 Cyclophosphamide 2 Cisplatin 2 Carboplatin 2 Capecitabine 2 pegylated granulocyte colony-stimulating factor 1 aumolertinib 1 Zoledronic Acid 1 Vinorelbine 1 TP protocol 1 Standard of Care 1 S 1 (combination) 1 Radiation Dose Hypofractionation 1 Platinum 1 Pemetrexed 1 Neoadjuvant Therapy 1 Irinotecan 1 Granulocyte Colony-Stimulating Factor 1 Drug Therapy 1 Decitabine 1 Chemotherapy, Adjuvant 1 Cetuximab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04762459 2022-02-24

APEX

ChineseAMS

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡